###### Strengths and limitations of this study

-   To our knowledge, this systematic review will be the first addressing sex as a prognostic factor for sepsis and its findings may help to stratify patients for treatment.

-   This systematic review will examine mortality outcomes, which are critical for patients and decision making.

-   There may be challenges for meta-analysing the results due to heterogeneity among primary studies.

Introduction {#s1}
============

Sepsis is currently defined as life-threatening organ dysfunction resulting from a dysregulated host response to inflammation.[@R1] Sepsis is a major health problem with a worldwide incidence of about 1 case per 1000 patients, making it the main cause of admission to an intensive care unit (ICU) in high-income countries.[@R2] Moreover, despite advances in healthcare, sepsis remains a leading cause of death every year and is the most common cause of death within the ICU.[@R4]

Sepsis is a heterogeneous disease affecting both male and female individuals.[@R7] Recently, it has been recognised that sex may contribute to a differential risk for developing sepsis; and it remains uncertain if the prognosis of sepsis varies between the sexes.[@R8] Prognosis factors are relevant in clinical care as they can identify risk groups in which clinical practice may be tailored to the aim of reducing morbidity and mortality.[@R15] The aim of this systematic review is to summarise the available evidence to assess the role of sex as a prognostic factor for mortality in patients with sepsis managed in the ICU.

Methods {#s2}
=======

Registration {#s2-1}
------------

We registered the protocol with an International Prospective Register of Systematic Reviews (PROSPERO) on 12 November 2019. Possible amendments will be updated on PROSPERO. The protocol is reported according to the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Protocols statement.[@R16] The review will be reported according to the PRISMA statement.[@R17]

Eligibility criteria {#s2-2}
--------------------

### Type of studies {#s2-2-1}

We will include experimental studies, randomised or not, and any observational study investigating the prognostic significance of sex in adults with sepsis managed in the ICU. Regarding prognostic factor studies, we will only include phase II confirmatory studies.

### Type of participants {#s2-2-2}

Adults (male and female individuals, which allow determining the role of sex) aged ≥16 years with a diagnosis of sepsis. We will accept the study authors' definition of sepsis and septic shock. For a study to be eligible, the sepsis must be managed in an ICU. Studies including adults, children and/or adolescents will be eligible if adults represent \>80% of the study sample.

### Type of prognostic factors {#s2-2-3}

We will include studies that assess sex as a prognostic factor. We will accept any assessment of sex as provided by the study authors. The concepts of sex and gender are distinct. Sex is a biological characteristic and gender refers to the socially constructed roles, behaviours and identities of women, men and gender-diverse individuals.[@R18] This review will not assess the association between gender and the outcomes of patients with sepsis in the ICU.

We will assess the role of sex as a prognostic factor after adjustment for additional covariates. After a literature search and a consensus process with clinician review authors, and as suggested during peer review of our protocol ([online supplementary appendix 1](#SP1){ref-type="supplementary-material"}), we agreed on the following core set of adjustment factors: age, severity score (Sequential Organ Failure Assessment socre (SOFA), Simplified Acute Physiology Score II (SAPS II) or Acute Physiologic Assessment and Chronic Health Evaluation II (APACHE II)), comorbidities (immunosuppression, pulmonary diseases, cancer, liver diseases and alcohol dependence), non-urinary source of infection, inappropriate or late antibiotic coverage.[@R19] We may modify this list if we find new evidence that justifies the changes.
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### Type of outcomes {#s2-2-4}

#### Primary outcomes {#s2-2-4-1}

-   All-cause hospital mortality (the longest follow-up provided by the study authors).

-   All-cause hospital mortality during the first 28 days.

#### Secondary outcomes {#s2-2-4-2}

-   All-cause hospital mortality during the first 7 days.

-   All-cause mortality at 1 year.

Information sources {#s2-3}
-------------------

We will search the following databases:

-   MEDLINE Ovid (from 1946 onwards).

-   Embase Elsevier (from 1974 onwards).

-   Web of Science (WoS).

Search methods {#s2-4}
--------------

The search strings will be based on terms related to the population (sepsis), the prognostic factor (sex), the outcome (mortality) and prognostic study methods.[@R27] For 'sex' we will use a search string adapted from Lorenzetti, Moerman, Song and Stewart[@R28]([online supplementary appendix 2](#SP2){ref-type="supplementary-material"}). We will not apply publication date or language restrictions.
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Moreover, we will check the bibliographic references for additional relevant studies. We will also scan ClinicalTrials.gov ([www.clinicaltrials.gov](www.clinicaltrials.gov)) and the WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch/) for unpublished and ongoing studies.

Furthermore, we will search for conference abstracts of major critical care and infectious diseases symposia from 2010.

1.  Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 50th edition 2010 to 59th edition 2019.

2.  European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 20th edition 2010 to 29th edition 2019.

3.  Society for Healthcare Epidemiology of America (SHEA): IDWeek 2012 to 2019 editions.

4.  International Conference on Prevention and Infection Control (ICPIC): 2011, 2013, 2015, 2017, 2019

5.  Society of Critical Care Medicine (SCCM): 39th edition 2010 to 48th edition 2019.

6.  International Symposium on Intensive Care and Emergency Medicine (ISICEM): 30th edition 2010 to 39th edition 2019.

7.  European Society of Intensive Care Medicine (ESICM): 2010 onwards.

Apart from that, we will contact experts on the topic to ask for any ongoing, missing or unreported studies.

Study records {#s3}
=============

Data management {#s3-1}
---------------

We will eliminate duplicates with Endnote 7.8 reference management software.[@R32] We will manage the resultant unique references with the online software EPPI-Reviewer to identify additional duplicates, select studies, build the data extraction templates and extract the data.[@R33]

Study selection and data collection {#s3-2}
-----------------------------------

Two of six review authors (AAM, AH, MPA, OM, RdC, PF) will independently screen retrieved results according to the best practice guidelines to determine whether they fulfil the eligibility criteria of this review.[@R34] We will use a consensus method, and a third author (JL-A, AAM, ES) will be consulted if there are disagreements. We will pilot eligibility criteria on a sample of references to ensure their reproducibility. Assessment of the eligibility of full texts will be undertaken similarly. Two of seven authors (JL-A, AAM, AH, MP, OM, RdC, PF) will independently extract data according to a pre-defined form and a third author will resolve the discrepancies (JL-A, AAM, ES). We will pilot the data extraction template with three studies to ensure its suitability. We will compare results and resolve discrepancies by discussion or by referring to a third review author.

Data items {#s3-3}
----------

We will use CHecklist for critical Appraisal and data extraction for systematic Reviews of prediction Modelling Studies for prognostic factor (CHARMS-PF) guidance for data collection.[@R35] This tool modifies the original CHARMS checklist for prediction model studies.[@R36] We will extract the following data from each eligible study:

1.  Publication date, country and setting in which the study was conducted.

2.  Study design: experimental study or observational study.

3.  Registration: presence of registration or protocol published (yes/no).

4.  Sepsis definition used by authors.

5.  Participant characteristics: participant description, eligibility criteria and details of treatment received (if applicable).

6.  Sex definition used by authors.

7.  Review outcomes reported in the study: mortality; type of measures (binary); follow-up period (the first 7 days, the first 28 days and the longest follow-up provided by the study authors).

8.  Missing data: attrition (quantification and reasons), handling of missing data by the study authors(available case analysis or imputation).

9.  Analysis: univariate analysis/logistic regression/Cox regression/other.

10. Estimates reported between the prognostic factor and each review outcome: (a) unadjusted estimate: association between sex and mortality with no covariate; (b) adjusted estimates: association/s between sex and mortality with at least one covariate.

11. Type of measure of association: odds ratio (OR), risk ratio (RR) or hazard ratio (HR).

12. List ofadjustment factors that were used. We will contact authors of individual studies for additional information if required.

Assessment of methodological quality and risk of bias {#s3-4}
-----------------------------------------------------

We will use the QUIPS (Quality In Prognosis Studies) tool to assess risk of bias.[@R35] Two review authors will independently assess the following six domains of the QUIPS tool: (1) study participation; (2) study attrition; (3) prognostic factor measurement; (4) outcome measurement; (5) adjustment for other prognostic factors; (6) statistical analysis and reporting.

We will make a judgement for every criterion, using one of four categories (low, moderate, high risk and unclear), adapting the QUIPS guidelines.[@R35] We will resolve disagreements by discussion, and a third author will be consulted if it is required.

We will evaluate the impact of risk of bias from primary studies by performing sensitivity analyses (see the Sensitivity analyses section).

Data synthesis {#s3-5}
--------------

For each study and prognostic effect estimate, we will extract the measures of association reported in each study (OR, RR, HR) along with its standard error (SE) or confidence intervals (CIs). We will transform association measures into OR with its 95% CI in order to allow statistical pooling whenever adequate.[@R39] We acknowledge that the studies providing the adjusted prognostic effect of a particular factor can differ in the set of adjustment factors. We will define a core set of adjustment factors for each review outcome.

If the study provides a set of adjustment factors that differ from our core set, we will meta-analyse the study but the estimate will be penalised as part of the risk of bias assessment. If the same study presents different estimates for the same outcome, each of them adjusted for different factors, we will extract the estimate that has adjusted for the maximum number of our key confounders for meta-analysis. If there are several estimations, all of them having adjusted for the same key confounders, we will consider the estimate adjusted for more confounders in total. We assume that this will minimise the risk of confounding bias in the estimation.

We plan to combine the results from individual studies in a meta-analysis to provide a pooled prognostic effect estimate for each outcome. We will carefully evaluate the censoring mechanisms assumed in the studies that have been analysed using time-to-event procedures (i.e., Cox proportional hazard models). If we conclude that there is a risk of bias due to informative censoring (e.g., when patients with better prognosis are discharged for the ICU), we will disregard HRs obtained in such studies. We plan to use the Hartung-Knapp-Sidik-Jonkman (HKSJ) method for random-effects meta-analysis. We will use the Cochrane statistical package Review Manager 5.3 for organising the text of the review, and if the meta-analysis is possible, we will use the metareg command in Stata (Stata V.15.1) for performing the meta-analysis with the HKSJ method.[@R40]

### Heterogeneity between studies {#s3-5-1}

When there are at least three studies, we will examine heterogeneity by calculating prediction intervals in order to inform how the effect varies across populations. The prediction interval is an index of dispersion that describes the range of effect sizes in which we would expect that the true effect size will fall.[@R41] We will use the spreadsheet provided by Borenstein *et al* for computing the prediction interval.[@R42]

If we judge that the meta-analysis is inappropriate for other reasons, we will not combine results and we will undertake a narrative analysis of studies.

To better understand the sources of heterogeneity, we plan to conduct the following subgroup analyses:

-   Trials versus cohort studies versus case--control studies.

-   Prospective studies (all the study parts were prospective) versus retrospective studies (all the study parts were retrospective).

### Sensitivity analyses {#s3-5-2}

We will undertake the following sensitivity analyses:

-   Evaluate the impact of risk of bias from individual trials in the overall effect. We will consider the following risk of bias domains as key domains for the analyses: study attrition, prognostic factor measurement, outcome measurement and adjustment for other prognostic factors.

-   We will exclude studies with a high risk of bias in at least one key domain.

-   We will exclude studies with a high or moderate risk of bias in at least one key domain.

-   Assess the effect of excluding studies that have provided an adjusted estimate, but that did not adjust for all our core set of additional prognostic factors.

Publication bias {#s3-6}
----------------

We will attempt to assess the presence of publication bias for each meta-analysis containing ≥10 studies by funnel plot representation and Peter's test at a 10% level.[@R43]

Confidence in cumulative evidence {#s3-7}
---------------------------------

We will attempt to use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and will present our results for each main outcome in a 'Summary of findings' table, although we acknowledge that the GRADE approach has not been widely used to assess the certainty of the evidence of prognostic factors.[@R44] We will follow the principles suggested in Hughet *et al* and Iorio *et al* for prognostic questions.[@R46] We will use GRADE profiler (GRADEpro GDT) for designing a 'Summary of findings'.[@R48]

Patients and public involvement {#s3-8}
-------------------------------

Patients and the general public will not be involved in the process of conducting this systematic review. We will not plan to involve patients in the dissemination of the results of this systematic review.

Ethics and dissemination {#s3-9}
------------------------

Ethical permission is not necessary as this study summarises published data. This review is part of the SEXCOMPLEX project (Influence of sex and sex hormones on human chronic disorders of complex aetiology), a 2-year project (2017--2019) coordinated by Hospital Ramón y Cajal (Madrid, Spain). We shall disseminate our findings through peer-reviewed publication, at conferences, and in the mass media.
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